The nesfatin 1 level in male patients with manic episode and alterations of nesfatin 1 level after antipsychotic and electroconvulsive treatment.
BACKGROUND
Nesfatin 1 is a newly identified peptide structured satiety hormone that is claimed to be responsible for the provision of appetite and metabolic regulation in hypothalamus. The change in appetite and energy is a well-known clinical feature of affective disorders and within treatment. We aimed to investigate serum nesfatin 1 level in patients with bipolar disorder who were in manic episode and the influences of treatment modalities on nesfatin 1 level.


METHODS
Sixty eight patients were elected and were divided into two groups as: antipsychotic treatment (haloperidol 10-30 mg/daily+quetiapine 100-900 mg/daily) arm and ECT+antipsychotic treatment arm. And 30 healthy controls were included in the study.


RESULTS
There was no significant difference according to mean age between patients and controls. Initial nesfatin 1 levels in patients and in both subgroups of patients were statistically lower than in healthy control group. The initial level of nesfatin 1 between ECT+antipsychotic and pure antipsychotic patient groups was not statistically significant. We found a trend of increment in nesfatin 1 level after treatment in both patient groups.


CONCLUSIONS
This study is the first that revealed significantly lower nesfatin 1 level in manic episode than healthy controls. ECT+antipsychotic and antipsychotic treatments have no significant effects on nesfatin 1 level after manic episode treatment. These findings should be interpreted cautiously because of small sample size and being drug free only for one week.
Department of Psychiatry and Department of Biochemistry, Medical School of Cerrahpasa, Istanbul University, Turkey.
Murat
M
Emul
Nesrin
N
Karamustafalioglu
Tevfik
T
Kalelioglu
Abdullah
A
Genc
Akif
A
Tasdemir
Ferda Can
FC
Gungor
Said
S
Incir
Arzu
A
Seven
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy; D002135:Calcium-Binding Proteins / Q000097:blood* / Q000502:physiology; D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000097:blood* / Q000502:physiology; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004565:Electroconvulsive Therapy; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000097:blood* / Q000502:physiology; D000080866:Nucleobindins; D000069348:Quetiapine Fumarate; D055815:Young Adult
D014150:Antipsychotic Agents; D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; D003987:Dibenzothiazepines; C000630650:NUCB2 protein, human; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins; D000069348:Quetiapine Fumarate; D006220:Haloperidol
Electroconvulsive therapy; Mania; Nesfatin